Cytokinetics

CYTK NASDAQ
11.14
-0.09
-0.80%
After Hours: 11.14 0 0.00% 18:41 07/19 EDT
Open
11.21
Prev Close
11.23
High
11.46
Low
11.05
Volume
859.34K
Avg Vol (3M)
482.58K
52 Week High
11.86
52 Week Low
5.75
% Turnover
1.49%
Market Cap
643.02M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Cytokinetics CYTK stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
MORE >

Recently

Name
Price
%Change